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Abstract  
BACKGROUND: Fetuin-A and ghrelin have been implicated in cardiovascular diseases and 
mortality among end stage renal disease patients. The exact mechanisms have not been fully 
elucidated. There is robust data supporting an association between ghrelin and various 
cardiovascular conditions, and some common processes such as inflammation, oxidative stress, 
and endoplasmic reticulum stress have been implicated.  
AIM: This study was conducted to assay serum fetuin-A and ghrelin in chronic renal failure pediatric 
patients and to study changes in their level that may occur after a single hemodialysis.  
MATERIAL AND METHODS: Forty nine pediatric patients suffering from ESRD on maintenance 
hemodialysis (HD), 20 patients with chronic renal failure (CRF) not on dialysis and 35 healthy 
subjects as control group were included. The mean age of the study population was 10.58 ± 3.94, 
10.62 ± 3.24 and 10.61 ± 3.97 years respectively. Serum fetuin-A and plasma acyl ghrelin levels 
were measured by using ELISA method.  
RESULTS: The present study revealed that predialysis serum fetuin-A level was significantly 
increased in pediatric HD patients compared with the normal population, while ghrelin levels were 
significantly reduced. Furthermore, serum levels of fetuin-A decreased significantly after a single 
HD session.  
CONCLUSION: Our study concluded that fetuin-A and acyl ghrelin may play a role in inflammatory 
process among HD pediatric patients which may account for cardiovascular insults and mortality 
but their use as biochemical markers among ESRD pediatric patients have limitations due to wide 
fluctuations.  
 
 
 
 
Introduction 
 
Hemodialysis (HD) patients experience a 
cardiovascular mortality of up to 20% per year, and 
vascular calcification is a strong independent risk 
factor of cardiovascular death [1, 2]. Fetuin-A (AHSG, 
a2-Heremans–Schimd glycoprotein) is an important 
inhibitor of vascular calcification [3, 4]. Fetuin uptake 
and secretion by proliferating and differentiating cells 
in the arterial wall is a protective mechanism against 
arterial calcification [5]. Circulating fetuin-A decreases 
in parallel with decline in renal function [6]. Reduced 
serum fetuin-A levels are associated with 
inflammation and increased cardiovascular mortality in 
hemodialysis [7]. 
Ghrelin, a peptide of 28 amino acids, was first 
reported by Kojima in rat and human stomachs in 
1999 [8]. There is robust data supporting an 
association between ghrelin and various 
cardiovascular conditions, and some common 
processes such as inflammation, oxidative stress, and 
endoplasmic reticulum stress have been implicated, 
although the exact mechanisms have not been fully 
elucidated [9]. Ghrelin may have cardiovascular 
protective effect, including lowering of blood pressure, 
regulation of atherosclerosis, and protection from 
ischemia/reperfusion injury as well as improving the 
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prognosis of myocardial infarction and heart failure. 
Some of these new functions of ghrelin may provide 
new potential therapeutic opportunities for ghrelin in 
cardiovascular medicine [9]. There is an urgent need 
for effective appetite-stimulatory therapies for chronic 
kidney disease (CKD) patients. Ghrelin is more potent 
than any other orexigenic factors as it rapidly 
enhances food consumption following injection in 
rodents [10] and humans [11]. Results of recent 
findings bolster the potential therapeutic application of 
ghrelin and its analogues as an appetite stimulating 
and anabolic strategy in uremia associated cachexia 
and other types of disease-associated cachexia. 
Ghrelin regulates metabolic balance and may improve 
the cachectic condition through IGF-dependent and 
IGF-independent pathways. Conflicting results of 
circulating ghrelin levels in CKD have been presented. 
Elevated plasma ghrelin levels were observed in adult 
dialysis patients than those of age-matched controls 
[12]. Szczepanska et al. reported that plasma ghrelin 
levels were similar in CKD children on dialysis 
compared with children on conservative treatment and 
healthy controls [13]. 
This study was primarily conducted to 
investigate changes in serum fetuin-A and plasma 
acyl ghrelin that may occur after a single hemodialysis 
in renal failure children and compare it to CRF and 
control children.  
 
 
Subjects and Methods 
 
This cross-sectional study was carried out on 
49 ESRD pediatric patients on maintenance 
hemodialysis and 20 patients with CRF not on dialysis 
recruited from the Pediatric Dialysis Unit, Cairo 
University Children Hospital. Thirty five healthy 
subjects were served as control group. The studied 
hemodialysis pediatric patients consisted of 22 
(44.8%) females and 27(55.2%) males. The mean age 
of the study population was 10.58 ± 3.94 years for 
hemodialysis patients, 10.62 ± 3.24 for CRF patients 
and 10.61 ± 3.97 years for controls. The mean time of 
dialysis of these patients suffering from ESRD was 
49.44 ± 33.25 months. Hemodialysis was performed 
thrice weekly for about 3 to 4 h per session at blood 
flow rates of 4-5 ml/kg/min using high flux polysulfone 
hollow-fiber filter. Exclusion criteria included active 
infection. The study was approved by the Ethical 
Committee of National Research Centre and informed 
consent was obtained in every case from their legal 
guardians. 
Demographic data, anthropometric 
measurements (weight, height, BMI, mid-arm 
circumference, triceps skin fold thickness), primary 
renal disease, dialysis duration, vital signs, and 
routine laboratory investigations were obtained. 
Systolic (SBP) and diastolic blood pressure (DBP) 
was measured with a standard clinical 
sphygmomanometer. Body mass index was 
calculated as weight divided by height squared for 
each patient (kg/m
2
). Routine laboratory investigations 
included complete blood count (using Coulter 
counter), calcium, phosphorous, alkaline 
phosphatase, creatinine, BUN, Na, K. 
For Serum fetuin-A and plasma acyl ghrelin 
levels assay, blood samples were collected before 
hemodialysis and also after hemodialysis. Fasting 
blood sample was collected from CRF patients and 
controls. All serum and plasma were frozen at -80°C. 
Serum fetuin-A levels in human subjects were 
measured using commercial enzyme-linked 
immunosorbent assays (ELISA, BioVendor Laboratory 
Medicine, Brno, Czech Republic), and plasma acyl 
ghrelin levels were measured by using ELISA method. 
Table 1: Characteristics of study participants   
Variables Hemodialysis 
(No = 49 
patients) 
CRF 
(No = 20) 
Controls 
(No = 35) 
P-value 
Age (years) mean ± SD  
Sex (M/F ratio) 
Body mass index (kg/m
2
)  
Duration of dialysis (years) 
Systolic blood pressure (mm Hg)  
Diastolic blood pressure (mm Hg)  
Hypertension 
Hb g/dl 
Hct % 
WBCs x10
3
/ μL  
Platelets x10
3
/ μL  
Ca (mg/dl) 
P (mg/dl) 
Alkaline phosphatase (IU/L) 
Albumin (mg/ml) 
Urea (mg/dl) 
Creatinine (mg/dl) 
Fetuin-A (μg/ml) 
Fetuin-A (post-dialysis) 
Acylated Ghrelin (pg/ml) 
Acylated Ghrelin (post-dialysis) 
Kidney disease diagnosis 
 Nephritis 
 UTI and obstructive uropathy 
 Congenital renal defects 
 Unknown 
10.58 ± 3.94 
27/22 
17.44 ± 2.88 
2.97 ± 1.78 
118.36 ± 18.41 
78.36 ± 12.72 
30/49 (61.2%) 
10.44 ± 2.20 
31.06 ± 8.91 
7.23 ± 2.57 
209.05 ± 92.02 
8.7 ± 1.03 
5.27 ± 1.57 
585.15 ± 357.9 
3.47 ± 0.32 
73.59 ± 30.55 
6.91 ± 2.2 
1093.9 ± 930.9 
503.67 ± 349.9 
127.28 ± 9.44 
132.13 ± 6.02 
 
7 (14.3%) 
23 (46.9%) 
7 (14.3%) 
12 (24.5%) 
10.62 ± 3.24 
10/10 
16.65 ± 3.68 
- 
89.23 ± 5.8 
58.46 ± 3.91 
0 
10.5 ± 1.57 
30.78 ± 3.94 
7.4 ± 2.73 
258.33 ± 75.78 
9.18 ± 1.28 
4.64 ± 0.82 
515.7 ± 323.2 
3.67 ± 0.47 
52.31 ± 21.51 
2.58 ± 1.28 
516.5 ± 54.1 
 
129.5 ± 3.5 
 
 
3 (15%) 
8 (40%) 
6 (30%) 
3 (15%) 
10.61 ± 3.97 
18/17 
20.23 ± 2.93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
449.1 ± 60.43 
 
140.21 ± 11.87 
>0.05 
>0.05 
<0.05 
 
 
 
 
 
 
 
 
 
UTI: urinary tract infection 
 
Statistical Analysis 
Standard computer program SPSS for 
Windows, release 13.0 (SPSS Inc., USA) was used 
for data entry and analysis. All numeric variables were 
expressed as mean ± standard error of mean (SE). 
Comparison of different variables in various groups 
was done using Student t test and Mann Whitney test 
for normal and nonparametric variables respectively. 
Pearson's and Spearman's correlation tests (r = 
correlation coefficient) were used for correlating 
normal and non-parametric variables respectively. For 
all tests, a probability (P) less than 0.05 (< 0.05) is 
considered significant. 
 
 
Results 
 
The characteristics of the study population are 
shown in Table 1. The primary renal diseases leading 
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to ESRD among HD pediatric children were urinary 
tract infection and obstructive uropathy (N = 23), 
glomerulonephritis (N = 7), congenital renal disease 
(N = 7), and unknown cause (N = 12). The differences 
between the mean of serum levels of fetuin-A and acyl 
ghrelin between HD patients compared with control 
population are shown in Table 2.  
Table 2: Comparison of serum fetuin-A and plasma ghrelin 
between pediatric dialysis patients and controls 
 N Mean ± SD Sig. (2-tailed) 
Fetuin- A predialysis 49 1093.94 ± 930.79  
.000 Control 35 449.06 ± 76.19 
Ghrelin predialysis 49 127.28 ± 9.44  
.000 Control 35 140.21 ± 11.87 
 
The present study showed that HD patients 
have significantly increased serum fetuin-A levels and 
reduced plasma ghrelin levels as compared with the 
normal population. Furthermore, serum levels of 
fetuin-A decreased significantly during a single HD 
session while plasma ghrelin was insignificantly 
affected (Table 3). The serum fetuin-A and acyl 
ghrelin in CRF patients was not significantly affected 
as compared to control. The correlation between 
serum fetuin-A and plasma ghrelin and 
anthropometric measures for patients and controls 
revealed significant negative correlation between 
fetuin-A in patients and weight (p value = 0.03). There 
were also positive significant correlations between 
blood pressure (systolic and diastolic) and weight and 
height. The correlations between fetuin-A and acyl 
ghrelin and renal function parameters revealed no 
significant correlation between them and GFR among 
CRF group.  
Table 3: Paired Samples Test for fetuin-A and ghrelin pre and 
postdialysis 
Paired Samples Test 
 
 
 
Paired Differences 
   t 
 
 
df 
 
 
Sig. (2-
tailed) 
 
 
Mean 
Std. 
Deviation 
Std. Error 
Mean 
95% 
Confidence 
Interval of 
the 
Difference 
   Lower Upper 
Pair 1 
Fetuin-A 
predialysis - 
Fetuin-A 
postdialysis 
559.16 814.77 235.20 41.48 1076.85 2.37 11 .037 
Pair 2 
 Ghrelin 
predialysis - 
Ghrelin 
postdialysis 
-4.01 12.55 2.29 -8.70 .67 -1.75 29 .090 
 
 
Discussion 
 
Pediatric patients suffering from ESRD, 
whether on regular dialysis or on conservative 
therapy, have a large burden of cardiovascular 
diseases. One of the important risk factor is 
inflammation. The results of the present study showed 
that patients with renal diseases whether on regular 
HD or on conservative therapy display various 
degrees of changes in some biochemical parameters. 
In adult studies, serum fetuin-A levels were 
significantly lower in hemodialysis patients as 
compared to CRF patients and controls [14, 15]. In 
pediatric patients, there was a controversy about the 
serum level of fetuin-A on regular hemodialysis. In this 
study, serum fetuin-A levels were significantly higher 
in hemodialysis pediatric patients as compared to 
CRF patients and controls while no significant 
difference was found between CRF patients and 
controls. Similar to our study, ZiÃ³Å et al study 
revealed that the serum fetuin-A in CRF patients was 
not significantly affected as compared to control [16]. 
Schaible et al study revealed that fetuin-A levels are 
clearly reduced in children on dialysis but not in those 
with moderate CKD and after transplantation [17]. 
Fetuin-A was lower in dialyzed and renal transplanted 
children compared with healthy controls [18]. Similar 
to our study, Shroff et al study on 16 children stated 
that physiological inhibitors of calcification, fetuin-A, 
osteoprotegerin (OPG) and under carboxylated-matrix 
Gla protein (uc-MGP) may play a role in preventing 
the development and progression of ectopic 
calcification, fetuin-A were higher in dialysis patients 
than controls. Fetuin-A showed an inverse correlation 
with dialysis vintage, time-averaged serum phosphate 
and hs-CRP [19]. Few studies in adult revealed that 
fetuin-A levels were significantly lower in the CKD 
group compared to the controls and no correlation 
between GFR and serum fetuin-A [7, 20, 21]. In 
Kayser et al study, serum fetuin-A concentrations 
were found to be decreased in all adult CKD patients 
but stage 1 CKD [22]. Cottone et al studies stated that 
plasma levels of fetuin-A were independently and 
directly associated with eGFR in CKD patients, 
showing a progressive and significant decrease 
related to decreasing eGFR [6, 23]. 
Regarding in vivo circulating modulators of 
calcification, fetuin-A is a circulating calcium-
regulatory protein inhibiting Ca=PO4 precipitation and 
it seems to be involved in both inflammation and 
vascular calcification processes. Actually, it is known 
that fetuin-A is down regulated during systemic 
inflammation as a negative acute phase protein [24]. 
In our study, serum fetuin-A level was significantly 
reduced after a single HD session. Ciaccio et al study 
concluded that the significant decrease of fetuin-A 
levels after a single HD session is consistent with the 
hypothesis of HD-induced inflammation [24]. Dusilova 
et al study found that serum concentrations of fetuin-A 
in hemodialysis (HD) patients are low. This decrease 
is conventionally explained by malnutrition and 
inflammation seen often in HD patients. Serum fetuin-
A decreased significantly during low-flux 
hemodialysis. The hemodialysis procedure itself is 
accompanied by a significant decrease of serum 
fetuin A, which may at least theoretically contribute to 
low serum fetuin-A concentrations generally observed 
in HD patients. This decrease is not related to bone 
mineral metabolism and/or inflammation markers. 
Because molecular weight of serum fetuin-A indicates 
no permeability of dialysis membrane, other yet 
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unknown mechanisms are involved in consumption of 
this molecule during HD [25]. Fetuin-A levels were 
independent of age, pubertal stage, and gender. 
Fetuin-A correlated significantly to systolic and 
diastolic blood pressure, Fetuin-A levels were higher 
in obese children with Non Alcoholic Fatty Liver 
Disease, and were related to insulin resistance and to 
features of the MetS in both cross-sectional and 
longitudinal analyses [26]. Safranek et al study in 
adult showed that low levels of fetuin-A are associated 
with malnutrition, inflammation, decreased bone mass 
density, low-turnover bone and use of high calcium 
concentration dialysate. Hemodialysis procedure (HD) 
has been shown to decrease fetuin-A levels by 20%, 
probably due to HD-induced inflammation or acute 
changes in calcium metabolism. Also Safranek et al 
study in adult concluded that standard bicarbonate HD 
with polysulfone dialyser and ultrapure dialysate 
induces only minor changes in fetuin-A [27]. 
Small studies of children with CKD stages 2 to 
4 or on dialysis therapy have shown rates of 
hyperinsulinemia as high as 33% and rates of 
abnormal insulin resistance (measured by increased 
Homeostasis Model Assessment for Insulin 
Resistance) in up to 16% of patients, indicating that 
abnormalities in insulin and glucose metabolism may 
be present earlier [28, 29]. 
There are several limitations to our study. 
First, this is a relatively small sample size. Second, 
the studies in pediatric age are few with controversial 
results. Third, there is considerable intrapatient 
variation fetuin-A. Tsirpanlis et al study and LaClair et 
al study followed patients for months; measuring 
weekly values; found variability in measured fetuin-A 
levels [30, 31]. LaClair et al study also measured four 
potential inflammatory biomarkers (CRP, IL-6, fetuin-
A, albumin), all of which have limited specificity for 
inflammation [31]. 
Acylated active form of ghrelin mediates 
appetite regulation [32]. One major effect of ghrelin is 
the increase of food intake with a subsequent 
increase of body weight, fat accumulation and 
increase in carbohydrate oxidation [33, 34]. Pediatric 
patients with ESRD often suffer from insufficient 
weight gain and growth retardation due to low appetite 
and low calorie intake. This uremic malnutrition is 
associated with high morbidity, poor quality of life and 
increased mortality rates. The ghrelin is now under 
trial in animals and human to be used as treatment to 
stimulate appetite in ESRD patients [35, 36]. 
In our study, plasma acyl ghrelin levels were 
significantly reduced in pediatric hemodialysis patients 
as compared to CRF patients on conservative 
treatment and controls. This may explain the loss of 
appetite among hemodialysis patients. Wynne et al. 
study tested the effects of subcutaneous ghrelin 
administration in CKD patients with mild to moderate 
malnutrition with improvement energy intake [37]. In 
comparison to other studies, there was conflicting 
results as regard plasma level of total ghrelin and 
acylated active form. Arbeiter et al. study [38] in 
pediatrics revealed that total ghrelin is significantly 
increased in CRF children which is similar to few 
studies in uremic children and adults [32, 39, 40, 41], 
while acyl ghrelin did not differ between hemodialysis, 
CRF, and control groups [41, 42]. Similar to our study, 
Montazerifar et al and Amanda de Faria Barros et al 
studies in adult revealed that acyl ghrelin 
concentration was significantly declined in HD patients 
when compared to healthy controls [43, 44]. Eftekhari 
et al study in children showed insignificant elevated 
total ghrelin [45]. In our study and others, the plasma 
acyl ghrelin is not significantly affected in spite of its 
clearance with hemodialysis [32, 40]. There were few 
limitations to our study on ghrelin. First, small sample 
size. Second, little is known about the regulation of 
ghrelin in children with CRF and during dialysis 
treatment since all studies included only few 
paediatric patients. Third, the ghrelin form assessed 
differed in different studies. In this study, acylated 
active ghrelin was assessed. Yoshimoto et al study 
revealed that the plasma level of the acylated active 
form of ghrelin is not raised in uremic patients, but 
instead the level of the non-acylated ghrelin [32]. 
Büscher et al study revealed that acyl ghrelin did not 
differ between groups; in children with CKD, children 
undergoing hemodialysis or peritoneal dialysis, renal 
transplant recipients, and healthy controls [42]. In our 
study, no correlation was found between GFR and 
acyl ghrelin which is similar to Naufel et al study [41], 
while in Arbeiter et al. study [38], and Naufelet al 
study [41] a negative correlation between glomerular 
filtration rate and total ghrelin was observed in CRF 
and transplant recipients. Fourth, despite animal 
models showing reduced clearance of ghrelin in 
rodent models of renal failure, conflicting results (i.e., 
increase, decrease, or no change) of circulating 
ghrelin concentrations in CKD patients have been 
reported. Szczepańska et al study found that plasma 
ghrelin levels were similar in children on APD and 
children on conservative treatment compared to 
healthy controls [13]. In another study, plasma ghrelin 
levels were markedly increased in HD and PD 
patients compared to healthy controls, while there was 
no difference between HD and PD patients [12]. 
Iglesias et al. study showed that patients undergoing 
HD have similar ghrelin concentrations in comparison 
with the control group. However, PD patients exhibited 
baseline ghrelin concentrations significantly lower 
than those found in patients on conservative 
management [46]. The available literature on plasma 
level of ghrelin in dialysis patients is not consistent, 
even within the same age range [46-48]. Plasma 
ghrelin levels increase before meals (rather than 
remaining low or stable), increase food intake (rather 
than increasing satiety), and decrease postprandial 
(rather than increasing) [49]. Due to this regulation, 
studies that include only a single fasting level may 
miss significant changes in 24-hour exposure that are 
due to alterations in postprandial suppression [50]. 
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Our study concluded that fetuin-A and acyl 
ghrelin may play a role in inflammatory process 
among HD pediatric patients which may account for 
cardiovascular insults and mortality but their use as 
biochemical markers among ESRD pediatric patients 
have limitations due to wide fluctuations.  
Future studies in pediatric ESRD patients' 
weather on conservative therapy or on hemodialysis 
are needed to learn more about the role of fetuin-A 
and ghrelin in diseased children. 
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